Pharmacology, clinical efficacy and safety of lamivudine in hepatitis B virus infection.

about

Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma

P2860

Q24234212-328C9753-4728-49DD-8335-DE3E0C4F6BEC Q24236020-70D0D753-FFAC-4F7F-8FD8-1D2AC9110122

P2860

Pharmacology, clinical efficacy and safety of lamivudine in hepatitis B virus infection.

Item

http://www.wikidata.org/entity/Q45388069

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Pharmacology, clinical efficacy and safety of lamivudine in hepatitis B virus infection.

@en

Pharmacology, clinical efficacy and safety of lamivudine in hepatitis B virus infection.

@nl

type

Item

label

Pharmacology, clinical efficacy and safety of lamivudine in hepatitis B virus infection.

@en

Pharmacology, clinical efficacy and safety of lamivudine in hepatitis B virus infection.

@nl

prefLabel

Pharmacology, clinical efficacy and safety of lamivudine in hepatitis B virus infection.

@en

Pharmacology, clinical efficacy and safety of lamivudine in hepatitis B virus infection.

@nl

P1476

Pharmacology, clinical efficacy and safety of lamivudine in hepatitis B virus infection.

@en

P2093

Manoj Kumar

http://www.w3.org/2001/XMLSchema#string

Shiv K Sarin

http://www.w3.org/2001/XMLSchema#string

P2860

Interferon and lamivudine vs. interferon for hepatitis B e antigen-positive hepatitis B treatment: meta-analysis of randomized controlled trials

Telbivudine versus lamivudine in patients with chronic hepatitis B

A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues

In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil

The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine

Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation

P304

465-495

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/17474124.2.4.465

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2008-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19072396

http://www.w3.org/2001/XMLSchema#string

P921

Farmakologi

Pharmacology, clinical efficacy and safety of lamivudine in hepatitis B virus infection.

about

P2860

P2860

Pharmacology, clinical efficacy and safety of lamivudine in hepatitis B virus infection.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921